CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety Evaluation of BCMA-UCART（Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03752541
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:39.238192+00:00
Published At: 2022-05-20T00:00:00+00:00
Record Updated At: 2022-05-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-05-20"
protocolSection.identificationModule.nctId: "NCT03752541"
protocolSection.identificationModule.officialTitle: "Efficacy and Safety Evaluation of BCMA-UCART\uff08Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor\uff09in the Treatment of Relapsed or Refractory Multiple Myeloma"
protocolSection.statusModule.overallStatus: "SUSPENDED"
protocolSection.designModule.phases: ["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.